glp-1 treatment for newly diagnosed diabetes guidelines Canada What Is a GLP-1 Journey:

Rare but important risks include pancreatitis, gallbladder problems, dehydration from severe vomiting/diarrhoea, and potential worsening of diabetic eye disease in people with diabetes

For example, studies on semaglutide 2.4 mg daily reveal an average 8% weight loss in individuals with diabetes over 60 weeks, while those without diabetes see closer to 11%

The other authors declare no competing interests

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)